Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
Type: Posted • Opportunity: RFA-DA-25-054
The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions
Category of Funding
Grant Program (CFDA)
Cost Sharing / Matching Requirement
On 1/29/24 the National Institutes of Health posted grant opportunity RFA-DA-25-054 for Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed). The grant will be issued under grant program 93.279 Drug Abuse and Addiction Research Programs.
Jan. 29, 2024, 12:00 a.m. EST
July 25, 2024, 12:00 a.m. EDT Due in 155 Days
Jan. 29, 2024, 11:30 a.m. EST
Aug. 30, 2024
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
National Institutes of Health
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Additional Information Site